파로스아이바이오

388870KOSDAQ자연과학 및 공학 연구개발업

48.0 / 100

Reference Date: 2026-06-10

Financial Score10.0 / 40

News Sentiment20.0 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Plunged 24.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Paros AI Bio is a R&D-focused company developing innovative drugs for rare and intractable diseases using its AI-based drug discovery platform, Chemiverse. Its lead pipeline, Lasmotinib (PHI-101), is an acute myeloid leukemia treatment designated as an orphan drug in the US, Korea, and Europe. The company also develops PHI-101-OC, a candidate for recurrent ovarian cancer. The platform enables faster drug development with reduced costs and higher success rates.

Number of Employees

33people

Average Salary

62.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

5.87Industry Average 3.241.0Point

1.8x industry avg (risky)

ROE

-66.12Industry Average -32.093.5Point

2.1x industry avg (excellent)

Debt Ratio

104.48Industry Average 7.310.0Point

14.3x industry avg (risky)

Trend 2023~20251.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

0.0 / 3

Avg ▼7.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -49.9% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 6Neutral 1Negative 0Average Sentiment Score 80

Positive
파로스아이바이오, 릴리 AI 신약개발 플랫폼 참여
파로스아이바이오의 AI 플랫폼 '케미버스'가 글로벌 제약사 릴리의 AI 신약개발 플랫폼과 연계되어 협력 계약을 체결함으로써 기술 혁신과 파트너십 강화로 긍정적 영향 기대.
Positive
파로스아이바이오, 일라이릴리 '튠랩' 전격 합류…엔비디아 AI 플랫폼....
파로스아이바이오의 글로벌 빅파마 일라이릴리와의 협업으로 AI 신약 개발 분야에서의 혁신적 기회 확대.
Positive
파로스아이바이오 대표, 자사주 매입…"책임 경영"
파로스아이바이오 대표의 자사주 매입으로 기업의 책임감 강화와 저평가 인식이 긍정적인 시장 반응을 이끌어냄.

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 6,310Won52-week high 11,62052-week low 4,745

1-month return0.0Point

1m -23.98% (strong drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-04
Neutral기타경영사항(자율공시) ([국책과제 선정] 보건복지부 주관 2026년도 구조기반 AI 신약개발지원 사업 협약 체결)2026-06-01
Neutral분기보고서 (2026.03)2026-05-14